As of March 14, 2025, there have been significant advancements in long-acting HIV prevention methods and new treatments for asthma.
Long-Acting HIV Prevention Injections
Gilead Sciences has developed lenacapavir, a long-acting injectable drug for HIV prevention. Clinical trials have demonstrated its high efficacy, with a 96% reduction in infections among participants. Lenacapavir is administered biannually, offering a more convenient alternative to daily oral PrEP regimens.
MARKETWATCH.COM
Efforts are underway to make lenacapavir accessible in low and middle-income countries by late 2025 or early 2026. Gilead has partnered with six generic drug manufacturers to produce affordable versions for 120 countries, pending regulatory approvals.
REUTERS.COM
However, challenges such as funding cuts have impacted the rollout of lenacapavir in certain regions, highlighting the need for alternative funding sources to ensure widespread accessibility.
Another long-acting injectable option is cabotegravir/rilpivirine (brand name Cabenuva), approved for use in several countries. This combination requires monthly or bimonthly intramuscular injections and has shown efficacy in maintaining viral suppression in individuals with HIV.
New Treatments for Asthma
Recent developments in asthma treatment include the introduction of biologic therapies targeting specific pathways involved in the disease. One such therapy is benralizumab, a monoclonal antibody that targets eosinophils, reducing asthma exacerbations and improving respiratory symptoms. Clinical studies have shown that benralizumab can decrease exacerbations by approximately 30%, offering a promising alternative to traditional steroid treatments with fewer side effects.
These advancements represent significant progress in the management and prevention of HIV and asthma, providing patients with more effective and convenient treatment options.
As of March 14, 2025, there have been significant advancements in long-acting HIV prevention methods and new treatments for asthma.
Long-Acting HIV Prevention Injections
Gilead Sciences has developed lenacapavir, a long-acting injectable drug for HIV prevention. Clinical trials have demonstrated its high efficacy, with a 96% reduction in infections among participants. Lenacapavir is administered biannually, offering a more convenient alternative to daily oral PrEP regimens.
MARKETWATCH.COM
Efforts are underway to make lenacapavir accessible in low and middle-income countries by late 2025 or early 2026. Gilead has partnered with six generic drug manufacturers to produce affordable versions for 120 countries, pending regulatory approvals.
REUTERS.COM
However, challenges such as funding cuts have impacted the rollout of lenacapavir in certain regions, highlighting the need for alternative funding sources to ensure widespread accessibility.
Another long-acting injectable option is cabotegravir/rilpivirine (brand name Cabenuva), approved for use in several countries. This combination requires monthly or bimonthly intramuscular injections and has shown efficacy in maintaining viral suppression in individuals with HIV.
New Treatments for Asthma
Recent developments in asthma treatment include the introduction of biologic therapies targeting specific pathways involved in the disease. One such therapy is benralizumab, a monoclonal antibody that targets eosinophils, reducing asthma exacerbations and improving respiratory symptoms. Clinical studies have shown that benralizumab can decrease exacerbations by approximately 30%, offering a promising alternative to traditional steroid treatments with fewer side effects.
These advancements represent significant progress in the management and prevention of HIV and asthma, providing patients with more effective and convenient treatment options.
